Tag: CARCINOGENS

Volume 11, Issue 31 from @Oncotarget reported that TQ decreased the expression levels of colorectal stem cell markers CD44 and Epithelial Cell Adhesion Molecule Ep CAM and proliferation marker Ki67 in colonospheres derived from both cell lines and…

The cover for issue 31 of Oncotarget features Figure 4, ‘Concentration dose-response curves of sirolimus effect [55 nM-1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure,’ by Vasuri, et al.

Oncotarget Volume 11, Issue 30 reported that recent evidence shows that the host innate immunity is also critical in sensing the presence of cytoplasmic DNA derived from genomic instability events, such as DNA damage and defective cell cycle progression

Oncotarget Volume 11, Issue 30 reported that genomic profiling of murine mammary tumor cells with differential VDR expression identified 35 transcripts that were altered by the 1,25D3-VDR complex including Hyaluronan Synthase-2

Volume 11, Issue 30 of Oncotarget reported that previously, the authors showed that anti-estrogen drugs combined with a dendritic cell-based anti-HER-2 vaccine known to induce strong Th1-polarized immunity dramatically improved clinical response rates in

The cover for issue 30 of Oncotarget features Figure 4, “RNAseq results demonstrating differences between normal, cancer, and redirected cells,” by Frank-Kamenetskii, et al. which reported that the influence of breast cancer cells on normal cells of the m

Oncotarget Volume 11, Issue 29 reported that In multivariate analyses, serum albumin, GNRI, pathological tumor-node-metastasis stage, and tumor differentiation were independent prognostic factors for CSS.

Oncotarget Volume 11, Issue 29 reported that Immunosuppressive chemoresistance is a major burden in lung cancer.

Oncotarget Volume 11, Issue 29 reported that acute myeloid leukemia is a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A, and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for

The cover for Issue 41 of Oncotarget features Figure 7, “IPA ATM-signaling pathway in (A) EFV treated MRC-5 and (B) A549 cells,” recently published in “Efavirenz induces DNA damage response pathway in lung cancer” by Marima, et al. which reported that the

Volume 11, Issue 26 of Oncotarget reported that Lung cancer is of particular importance, as it is the deadliest cancer worldwide.

Volume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by quantitative PCR.

Volume 11, Issue 28 of Oncotarget features “Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice” by Xu et, al. which reported that the authors exami

Volume 11, Issue 28 of Oncotarget features “Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation” by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines

Volume 11, Issue 28 of Oncotarget features ‘Rapid onset type 1 diabetes with anti-PD-1 directed therapy’, by Yun et al. and reported that Type 1 diabetes is a rare immune-related adverse event caused by checkpoint inhibitors with serious risk for diabetic

The cover for issue 40 of Oncotarget features Figure 5, ‘miR-210 silences the proapoptosis member CASP8AP2,’ by Kling, et al. which reported that hypoxic Ewing’s sarcoma cells release exosomes that promote sphere formation, a stem-like phenotype, in EWS

The cover for issue 38 of Oncotarget features Figure 3, ‘Summary of the time and cost for drug development (modified from DiMasi et al [2016],’ by Katayama, et al. which reported that Pancreatic cancer is the most aggressive common cancer and is desperate

INDIANAPOLIS–A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center has been awarded a five-year, $5.7 million National Cancer Institute grant to evaluate long-term health outcomes for cancer patients who receive platinum-based chemotherapies. An internationally recognized expert…